Quick Answer
GeneDx Holdings Corp. reported Cash And Cash Equivalents At Carrying Value of $105.00 million for the year ending 2025.
- GeneDx Holdings Corp. showed an increase of +23.2% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from GeneDx Holdings Corp.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2020 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $1.14 million | Q1 2022: $315.00 million | Q2 2022: $284.65 million | Q3 2022: $191.36 million | Q1 2023: $201.90 million | Q2 2023: $156.66 million | Q3 2023: $87.39 million | Q1 2024: $83.67 million | Q2 2024: $56.08 million | Q3 2024: $57.89 million | Q1 2025: $99.70 million | Q2 2025: $74.12 million | Q3 2025: $95.97 million.
- Over the full 9 years of available data (2020 to 2025), GeneDx Holdings Corp.'s Cash And Cash Equivalents At Carrying Value has declined by 2.9%.
- Historical annual values: Fiscal year 2025: $105.00 million | Fiscal year 2024: $85.21 million | Fiscal year 2023: $99.68 million | Fiscal year 2022: $123.93 million | Fiscal year 2021: $400.57 million | Fiscal year 2021: $461.28 million | Fiscal year 2021: $26.50 million | Fiscal year 2021: $58.65 million | Fiscal year 2020: $108.13 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: